Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Shareholder Meeting (September 2020)
13 slides from Amplia Therapeutics's shareholder meeting presentation, Sep 18, 2020
Slide 1: 2020 Annual General Meeting CEO Presentation
2020 Annual General Meeting CEO Presentation 18 September 2020 Amplia Therapeutics Limited
Slide 2: Disclaimer
Disclaimer The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. No representation or warranty, express or implied, is made in relation to the a
Slide 3: Company Highlights
Company Highlights Developing small molecule drugs against Focal Adhesion Kinase (FAK) for two, significant disease areas: • cancer – combination therapy in hard-to-treat solid tumours • fibrosis – prevention and treatment Orphan Drug Designations (ODDs) for both pancreatic cancer and idiopathic pul
Slide 4: Amplia FAKi's provide a broad opportunity set
Amplia FAKi’s provide a broad opportunity set AMP945 and AMP886 provide Amplia with several commercial opportunities Amplia is taking three approaches realise these opportunities: 1. take AMP945 into clinical development for pancreatic cancer and idiopathic lung fibrosis (both granted Orphan Drug De
Slide 5: Company snapshot
Company snapshot1 Shares 106.3M ATX Price and Volume – 12 months Market cap $16.0M Options 14.1M Cash 2 $4.0M Last qtr burn 3 ($0.4M) Listed May 2018 (RTO) Headquarters Melbourne Board Warwick Tong (Chair) John Lambert (MD) Robert Peach (NED) Chris Burns (NED) Substantial institutional Platinum – 16
Slide 6: Achievements in FY2020
Achievements in FY2020 Apr 2019 – European patent covering AMP945 until 2034 granted Jun 2019 – Preliminary dose-finding animal toxicology studies completed Jun 2019 – Dr John Lambert appointed as CEO Jul 2019 – Preclinical data on use of AMP945 to treat squamous cell carcinoma reported Jul 2019 – P
Slide 7: Achievements since Mar 2020
Achievements since 30 Mar 2020 May 2020 – Orphan Drug Designation awarded for idiopathic pulmonary fibrosis Jun 2020 – Completed toxicology studies required to support Phase 1 clinical trial Jul 2020 – Rights Issue raising $4.0M at $0.10/share Aug 2020 – Dr Mark Devlin appointed as Chief Scientific
Slide 8: Phase 1 Trial of AMP945
Phase 1 Trial of AMP945 First clinical trial of AMP945 will commence dosing in October 2020: • GMP clinical manufacture complete (kg scale) • Preclinical toxicology studies complete • Nucleus Network selected to manage trial being conducted at the Alfred Hospital • Clearance received from Human Rese
Slide 9: AMP945 – treatment of solid tumours
AMP945 – treatment of solid tumours Pancreatic cancer • FDA Orphan Drug Designation for AMP945 in the treatment of pancreatic cancer received in March 2020 • Collaboration with Prof. Paul Timpson at the Garvan Institute to assess novel dosing regimes and combination therapies for pancreatic cancer •
Slide 10: FAK in Idiopathic Pulmonary Fibrosis
FAK in Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a devastating, progressive disease caused by the build-up of fibrotic tissue in the lung which affects 3M people worldwide, including 130,000 in the US Left untreated, the median survival time is 2-3 years, with lung transpl
Slide 11: AMP945 – 18-month development plan
AMP945 – 18-month development plan CY2020 CY2021 Activity Q3 Q4 Q1 Q2 Q3 Q4 Phase 1 – healthy volunteers Phase 1 – data IND filing Non-clinical studies Phase 2 planning Phase 2 – cancer & IPF 11
Slide 12: Upcoming targeted milestones
Upcoming targeted milestones • Oct 2020 - Initiate dosing for SAD arm of Phase 1 clinical trial • Dec 2020 - Initiate dosing for MAD arm of Phase 1 clinical trial • Q2 2021 - Selection of first indication for Phase 2 based on preclinical combo studies • Q2 2021 - Headline data from both SAD and MAD
Slide 13: ampliatx.com
VANaatelite! Exposing cancer. Enhancing treatment. ampliatx.com
Amplia Therapeutics — Shareholder Meeting (September 2020) on 6ix